No changes were found in the CYP3A4 mRNA level in human fatty liver samples at various stages of NAFLD progression, however a trend of decreasing activity and protein levels was observed (Fisher et al., 2009b). This evidence concerns the gene CYP3A4 and metabolic dysfunction-associated steatotic liver disease.